NEW YORK (GenomeWeb News) – Cancer Genetics today said that its first-quarter revenues jumped 45 percent year over year, as it reported financial results for the first time as a publicly traded company.

Revenues for the three months ended March 31 were $1.2 million, compared to $834,752 during the first quarter in 2012. Clinical test volume increased to 1,911 tests in the quarter, up 19 percent from 1,610 in the year-ago period, while average revenue per test rose 23 percent to $615 from $502 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.